Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -0.93% | 166.03 | 0.7% | $1112.73m | |
| PFE | Pfizer Inc. | -1.52% | 48.52 | 0.9% | $899.70m | |
| LLY | Eli Lilly & Co. | -0.59% | 314.97 | 1.1% | $806.13m | |
| MRK | Merck & Co., Inc. | -0.15% | 90.91 | 0.7% | $786.71m | |
| ABBV | AbbVie, Inc. | -0.86% | 140.22 | 1.9% | $785.39m | |
| BMY | Bristol-Myers Squibb Co. | -1.19% | 73.68 | 1.0% | $631.07m | |
| SIGA | SIGA Technologies, Inc. | -7.16% | 23.00 | 0.0% | $433.56m | |
| AZN | AstraZeneca Plc | -0.21% | 66.28 | 1.0% | $363.29m | |
| GBT | Global Blood Therapeutics, Inc. | 0.18% | 67.12 | 5.6% | $345.41m | |
| GSK | GSK Plc | -0.97% | 33.98 | 0.3% | $286.14m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 0.07% | 223.28 | 8.2% | $270.23m | |
| HZNP | Horizon Therapeutics Plc | -1.76% | 60.65 | 5.4% | $218.20m | |
| CCXI | ChemoCentryx, Inc. | 0.37% | 50.97 | 2.9% | $209.16m | |
| KRTX | Karuna Therapeutics, Inc. | -0.81% | 259.12 | 0.0% | $202.59m | |
| VERU | Veru, Inc. | -20.16% | 18.99 | 0.0% | $194.84m |
Company Profile
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment consists of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment involves packaging, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.